XBP1 and Miyoshi myopathy: MK3946, an IRE1α endoribonuclease domain inhibitor, blocked XBP1 splicing causing death of MM cells and/or enhanced sensitivity of MM cells to other ER stress-inducing drugs bortezomib and 17-AAG, thereby proving to be of efficient lead for MM treatment (Mimura et al., 2012).